ID: ALA4450426

Max Phase: Preclinical

Molecular Formula: C13H12F3N7O

Molecular Weight: 339.28

Molecule Type: Unknown

Representations

Canonical SMILES:  N=C(N)NC(=O)c1nc(-c2ccc(C(F)(F)F)cc2)c(N)nc1N

Standard InChI:  InChI=1S/C13H12F3N7O/c14-13(15,16)6-3-1-5(2-4-6)7-9(17)22-10(18)8(21-7)11(24)23-12(19)20/h1-4H,(H4,17,18,22)(H4,19,20,23,24)

Standard InChI Key:  VTLAFUVKZLBWSY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 339.28

Molecular Weight (Monoisotopic): 339.1055

AlogP: 0.95

#Rotatable Bonds: 2

Polar Surface Area: 156.79

Molecular Species: NEUTRAL

HBA: 6

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.86

CX Basic pKa: 6.76

CX LogP: 1.59

CX LogD: 1.50

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.40

Np Likeness Score: -0.63

References

1. Buckley BJ, Majed H, Aboelela A, Minaei E, Jiang L, Fildes K, Cheung CY, Johnson D, Bachovchin D, Cook GM, Huang M, Ranson M, Kelso MJ..  (2019)  6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.,  29  (24): [PMID:31679971] [10.1016/j.bmcl.2019.126753]

2. Buckley BJ,Aboelela A,Majed H,Bujaroski RS,White KL,Powell AK,Wang W,Katneni K,Saunders J,Shackleford DM,Charman SA,Cook GM,Kelso MJ,Ranson M.  (2021)  Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.,  37  [PMID:33799173] [10.1016/j.bmc.2021.116116]

Source

Source(1):

• Scientific Literature